Healthigo

Health  Articles

Body
The future of insulin: Pills, patches, weekly formulation could change diabetes management

Today, there are six main types of insulin produced by the three insulin manufacturers serving the U.S. market, each varying by onset, peak and duration of action: rapid-acting, short-acting or “regular” insulin, intermediate-acting, long-acting, ultra-long acting, and “premixed” insulin, a combination of intermediate and short-acting formulations. A fast-acting insulin aspart injection (Fiasp, Novo Nordisk), described as the only mealtime insulin without a premeal dosing recommendation, was approved for children with diabetes as young as age 2 years in January. Promise of insulin pills Oral delivery is the simplest and least invasive way to deliver many pharmaceuticals, but many agents, including insulin, cannot survive passage through the stomach or the gastrointestinal (GI) tract, Grunberger said. Inhaled insulin An inhaled rapid-acting mealtime insulin (Afrezza, MannKind), approved by the FDA in 2015 to improve glycemic response in people with type 1 and type 2 diabetes, is known for its ability to address postprandial hyperglycemia, Grunberger said. The drug, which starts working 12 to 15 minutes after inhalation, was approved nearly a decade after the first FDA-approved powdered native human insulin (Exubera, Pfizer) was withdrawn from the market in 2007 due to low sales. Smart’ insulin patch In February, researchers from UCLA, the University of North Carolina School of Medicine and MIT announced the successful test of a smart insulin-delivery patch that could one day monitor and manage glucose levels for people with diabetes and deliver the necessary insulin dose. Weekly formulation PhaseBio is developing PE0139, a so-called super-long-acting basal insulin for people with diabetes dosed as a once-weekly injection. PE0139 is a fully mature, native insulin molecule (B and A chains) genetically fused to an elastin-like polypeptide (ELP) biopolymer. The compound is manufactured using PhaseBio’s ELP-based Escherichia coli expression system, where refolding of the drug occurs naturally in the cytosol, according to the company.

  1 Likes
  1 Comments
December 30, 2020
Ivan Gutierrez
Life, Health and everything in between.
Body
Female Infertility

About 17% of couples in industrialised countries seek help for infertility, which may be caused by ovulatory failure, tubal damage or endometriosis, or a low sperm count. In developed countries, 80% to 90% of couples attempting to conceive are successful after 1 year and 95% after 2 years. Methods and outcomes We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for infertility caused by ovulation disorders? What are the effects of treatments for tubal infertility? What are the effects of treatments for infertility associated with endometriosis? What are the effects of treatments for unexplained infertility? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

  0 Likes
  0 Comments
December 30, 2020
Test Doctor K
AS
Body
Why hair fallen will happen

Hair Fallen

  0 Likes
  0 Comments
December 30, 2020
Jenny S
Aesthetics
Body
Aesthetics

HA

  0 Likes
  0 Comments
December 30, 2020
Jenny S
aesthetics
Body
Factors influencing blood pressure levels

An important topic, upon which an initial group of articles are focused, is that of the factors influencing blood pressure levels. The issue opens with a Consensus Document produced by the Working Group on Obesity, Diabetes and the High Risk Patient of the European Society of Hypertension regarding the pathogenesis of obesity-induced hypertension (Kotsis et al., pp. 1499–1508). Although obesity is clearly associated with an increased prevalence of hypertension, it is also known that many obese individuals do not develop hypertension. The expert Consensus Document clearly discusses a number of protective and promoting factors for hypertension in obesity, and highlights gaps in our current knowledge. Within the same area of the influences of obesity on blood pressure, a large population study in China by Wang et al. (pp. 1555–1562) shows that measurements of the visceral fat index (VFI) or of the VFI to percentage body fat ratio (VFI/PBF) may provide a better understanding of adiposity-related risks for hypertension and prehypertension.

  0 Likes
  0 Comments
December 30, 2020
Mohamed Hassan
GP
scroll-arrow-to-up